- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03185832
Heart Failure and Sudden Cardiac Death Japan Registry (HINODE)
Heart Failure Indication and Sudden Cardiac Death Prevention Trial Japan
The purpose of this observational registry is to collect clinical events and outcome data in 4 different study populations (cohorts), with a majority of Japanese subjects, that are at risk of sudden cardiac death (SCD) and heart failure (HF) events. These event rates will be compared with available published data mainly from Europe and the United States.
Selected Subject Cohorts:
- Selected subject cohort with criteria for SCD (without spontaneous prior ventricular sustained arrhythmia) and de novo Implantable Cardioverter-Defibrillator (ICD) device treatment.
- Selected subject cohort with criteria for SCD and widely accepted standard cardiac resynchronization therapy (CRT) indication who received a de novo CRT-Defibrillator (CRT-D) device treatment.
- Selected subject cohort who are clinically expected to require >40% right ventricular pacing with a left ventricular ejection fraction (LVEF) ≤50%, any determined New York Heart Association (NYHA) Class, and receiving pacemaker (PM) or CRT-Pacemaker (CRT-P) therapy despite previous device history (de novo, box changes, system revisions or upgrades).
- Selected subject cohort with criteria for SCD fulfilling European Society of Cardiology (ESC) ICD or CRT-D therapy guidelines (2016) with an LVEF ≤35%, having 2 to 5 predefined SCD risk factors but do not have or had have a cardiac implanted defibrillator, CRT-D, PM, or CRT-P.
The primary endpoint will report on the Composite rate of first appropriately treated ventricular arrhythmia (by anti-tachycardia pacing [ATP] or shock) or life-threatening symptoms associated to ventricular arrhythmia (defined as hemodynamic instability which requires treatment), whichever comes first under MADIT RIT Arm B or C programming conditions in a study population with a majority of Japanese subjects. This primary end point is assessed in the ICD/CRT-D implanted patient cohort.
The all-cause mortality in subjects with a maximum of 3 risk factors (analyzed for MADIT II data) will be assessed in the Pacing (PM/CRT-P) patient cohort.
The all-cause mortality will be assessed in the non-implanted subject cohort.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Fukuoka, Japan, 812-8582
- Kyushu University Hospital
-
Fukuoka, Japan, 802-8555
- Kokura Memorial Hospital
-
Okayama, Japan, 700-8558
- Okayama University Hospital
-
Osaka, Japan, 558-8558
- Osaka General Medical Center
-
Osaka, Japan, 530-0001
- Sakurabashi Watanabe Hospital
-
Saitama, Japan, 330-8553
- Japanese Red Cross Saitama Hospital
-
Saitama, Japan, 330-8503
- Jichi Medical University Saitama Medical Center
-
-
Aichi
-
Ichinomiya, Aichi, Japan, 491-8558
- Ichinomiya Municipal Hospital
-
Nagoya, Aichi, Japan, 466-8560
- Nagoya University Hospital
-
Nagoya, Aichi, Japan, 466-8650
- Japanese Red Cross Nagoya Daini Hospital
-
-
Chiba
-
Sakura, Chiba, Japan, 285-8741
- Toho University Sakura Medical Center
-
Urayasu, Chiba, Japan, 279-0021
- Juntendo University Urayasu Hospital
-
-
Fukuoka
-
Kasuga, Fukuoka, Japan, 816-0864
- Fukuoka Tokushukai Hospital
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan, 060-8543
- Sapporo Medical University Hospital
-
Sapporo, Hokkaido, Japan, 065-0033
- Sapporo Higashi Tokushukai Hospital
-
-
Hyogo
-
Amagasaki, Hyogo, Japan, 660-8511
- Kansai Rosai Hospital
-
Himeji, Hyogo, Japan, 670-0981
- Hyogo Brain and Heart Center
-
-
Ibaraki
-
Hitachi, Ibaraki, Japan, 317-0077
- Hitachi General Hospital
-
Tsukuba, Ibaraki, Japan, 305-8576
- University of Tsukuba Hospital
-
-
Kanagawa
-
Kawasaki, Kanagawa, Japan, 216-8511
- St. Marianna University School of Medicine Hospital
-
Yokohama, Kanagawa, Japan, 222-0036
- Yokohama Rosai Hospital
-
Yokohama, Kanagawa, Japan, 236-0037
- Yokohama Minami Kyousai Hospital
-
Yokohama, Kanagawa, Japan, 241-0811
- St. Marianna University School of Medicine, Yokohama City Seibu Hospital
-
-
Miyagi
-
Sendai, Miyagi, Japan, 980-8574
- Tohoku University Hospital
-
-
Osaka
-
Suita, Osaka, Japan, 565-0871
- Osaka University Hospital
-
Suita, Osaka, Japan, 564-8565
- National Cerebral and Cardiovascular Center Hospital
-
-
Tochigi
-
Shimotsuke, Tochigi, Japan, 329-0498
- Jichi Medical University Hospital
-
-
Tokyo
-
Bunkyo, Tokyo, Japan, 113-8519
- Tokyo Medical And Dental University Medical Hospital
-
Bunkyō, Tokyo, Japan, 113-8603
- Nippon Medical School Hospital
-
Chuo, Tokyo, Japan, 104-8560
- St. Luke's International Hospital
-
Meguro, Tokyo, Japan, 153-8515
- Toho University Ohashi Medicine Center
-
Shibuya, Tokyo, Japan, 150-0013
- Tokyo Metropolitan Hiroo Hospital
-
Ōta, Tokyo, Japan, 143-8541
- Toho University Omori Medical Center
-
-
Yamaguchi
-
Ube, Yamaguchi, Japan, 755-8505
- Yamaguchi University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
General Inclusion Criteria:
- Subject is aged 20 or above
- Subject is willing and capable of providing informed consent
- Subject is willing and capable of participating in all visits associated with this study at an approved clinical study site and at the intervals defined by this Clinical Investigation Plan (CIP)
Measured Ejection fraction value obtained by echocardiography or equivalent method as Standard of Care (SOC):
- Device cohorts: within the last 3 months prior to enrolment
- Non-device cohort: latest available within the last 12 months prior to enrollment in case there was no documented HF decompensation, myocardial infarction (MI) or revascularization, otherwise within the last 3 months prior to enrollment
And 12 lead electrocardiogram (ECG) recording available as SOC:
- Device cohorts: pre-implant ECG maximum 45 days before implant; post-implant ECG
- Non-device cohort: latest available maximum 12 months prior to enrollment and subject agrees in the data being used for this study
General Exclusion Criteria:
Subject is enrolled in any other concurrent study without prior written approval from Boston Scientific (BSC), with the exception of local mandatory governmental registries and observational studies/registries that are not in conflict and do not affect the following:
- Schedule of procedures for the HINODE Study (i.e. should not cause additional or missed visits)
- HINODE Study outcome
- Conduct of the HINODE Study per Good Clinical Practice /International Standard Organization 14155:2011/local regulations as applicable
- Device implant revision is scheduled due to unstable result of an implant <45 days prior enrolment
- Subjects with more than 5 of the following risk factors: LVEF <35%, NYHA Class III or IV, left bundle branch block (LBBB) with QRS > 130 ms or QRS ≥150 ms, renal dysfunction (chronically BUN >26 mg/dL / ≥9.28 mmol/L), diabetes type I and II, chronic atrial fibrillation (permanent or persistent according to ESC Guideline 2016), prior MI, age >70 years, smoking today or during last 5 years
- Subjects with chronic renal disease with chronic BUN ≥50mg/dL or creatinine ≥2.5 mg/dL
- Subjects with coronary artery bypass graft (CABG) surgery or percutaneous coronary intervention (PCI) within the past three calendar months prior to enrollment
- Subjects with enzyme-positive myocardial infarction within the past three calendar months prior to enrollment
- Subjects who are expected to survive for <1 year with good functional status
- Subject's physician does not allow participation
- Subject is not willing and capable of participating in all testing or visits associated with this clinical study at an approved clinical study center and at the intervals defined by this CIP
- Unwilling to sign the consent for participation
- Women of childbearing potential who are or might be pregnant at the time of study enrolment
- ICD and CRT-D cohorts: implanted with a non-BSC device system. PM/CRT-P cohorts: implanted with a non-BSC pulse generator device.
Additional eligibility criteria apply to each cohort
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
CRT-D Cohort
Number of participants with first appropriately treated ventricular arrhythmia
|
This subject cohort is made by all patients enrolled and implanted with defibrillator with CRT capabilities
|
ICD Cohort
Number of participants with first appropriately treated ventricular arrhythmia
|
This subject cohort is made by all patients enrolled and implanted with defibrillator capabilities
|
Pacing (PM / CRT-P) Cohort
All cause mortality
|
This subject cohort is made by all patients enrolled and implanted with pacemakers with or without CRT capabilities
|
Non-device Cohort
All-cause mortality in the subject cohort with 2 to 5 predefined SCD driving risk factors
|
Patient enrolled but not implanted with a Defibrillator or Pacemaker
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Ventricular Arrhythmia Associated Symptoms - ICD/CRT-D Cohorts
Time Frame: 12 months follow up
|
Number of Participants with first appropriately treated ventricular arrhythmia (by anti tachycardia pacing [ATP] or shock) or life-threatening symptoms associated to ventricular arrhythmia (defined as hemodynamic instability which requires treatment), whichever comes first under MADIT Arm B or C programming conditions in a study population with a majority of Japanese subjects.
|
12 months follow up
|
Number of Participant Deaths - Pacing Cohort
Time Frame: 12 months follow up
|
All-cause mortality in subjects with a maximum of 3 risk factors (analyzed for MADIT II data).
|
12 months follow up
|
Number of Participant Deaths - Non-Device Cohort
Time Frame: 12 months follow up
|
All-cause mortality in the subject cohort with 2 to 5 predefined SCD driving risk factors.
|
12 months follow up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participant Deaths - ICD/CRT-D Cohorts
Time Frame: 12 months follow up
|
All-cause mortality for the ICD and the CRT-D cohorts.
|
12 months follow up
|
Number of Participants With Composite HF Event - ICD/CRT-D/Pacing Cohorts
Time Frame: 12 months follow up
|
Number of Participants with HF events, which require intravenous (IV) treatment and/or heart failure (HF) related hospitalization, or which led to HF death
|
12 months follow up
|
Number of Participants With Complication - ICD/CRT-D/Pacing Cohorts
Time Frame: 12 months follow up
|
Complication refers to qualified serious adverse device effects (SADEs) post success implantation, such as re-implant procedure, required invasive procedure related to the device system, pacing exit block, all-cause infection, and death due to therapy failure.
|
12 months follow up
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kazutaka Aonuma, Professor, University of Tsukuba Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C2076
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
US Department of Veterans AffairsCompleted
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
Clinical Trials on CRT-D
-
University Medical Center GroningenMaastricht University Medical Center; UMC Utrecht; Academisch Medisch Centrum... and other collaboratorsCompleted
-
University Hospital OlomoucNot yet recruiting
-
Abbott Medical DevicesCompleted
-
Medtronic Bakken Research CenterMedtronicTerminatedHeart Failure, CongestiveGermany
-
Semmelweis University Heart and Vascular CenterSheba Medical Center; University of Rochester; Pharmahungary GroupCompletedCardiomyopathyHungary, Germany, Serbia, Slovenia, Israel, Poland, Slovakia
-
Boston Scientific CorporationCompleted
-
Boston Scientific CorporationCompletedLeft Ventricular DysfunctionUnited States
-
University of Rome Tor VergataUnknownHeart Failure | Ventricular Fibrillation | Ventricular TachycardiaItaly
-
Boston Scientific CorporationCompletedHeart Failure | Atrial Fibrillation | Ventricular Fibrillation | Tachycardia | Atrial FlutterGermany
-
Helios Health Institute GmbHHeart Center Leipzig - University HospitalTerminatedChronic Heart FailureGermany